Caplyta Success in Major Depression; Mental Illness and Aging; New PTSD Device OK'd

(MedPage Today) -- Once-daily lumateperone (Caplyta, 42 mg) as monotherapy met its primary endpoint in a trial of major depressive disorder or bipolar depression with mixed features, significantly reducing symptoms and severity over 6 weeks versus...
Source: MedPage Today Psychiatry - Category: Psychiatry Source Type: news